USA Daniel Camardo is the President of Immedica Pharma US Inc. (Immedica), the US affiliate/subsidiary of Immedica Pharma AB, a Sweden-based rare disease company that entered the American market in 2024. Bringing together his experience building Astellas’s US presence and leading rare disease commercialization at Horizon, Camardo joined Immedica to lead…
Germany Our ambition is not simply to bring medicines to market, but to help improve the way dermatology patients are cared for As healthcare systems come under increasing pressure to deliver better outcomes with finite resources, dermatology is evolving beyond medicines alone. Kim Abbenhaus discusses how LEO Pharma is combining scientific…
Europe The goal is not only to generate scientific breakthroughs, but to ensure that these breakthroughs reach patients faster and more reliably Professor Gerd Geisslinger serves as Chair of Clinical Pharmacology at Goethe University Hospital and as Executive Director of the Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), which is…
USA We have spent the past decade building a strong foundation, investing in the market, expanding our capabilities, and assembling an exceptional team The US generics industry remains central to the healthcare system’s efforts to improve affordability, strengthen supply resilience, and expand patient access to medicines. As Cipla enters its second…
USA What motivates me is the opportunity to improve medical practice in a meaningful way, rather than simply bringing another product to market In an industry where genuine differentiation is becoming harder to find, Barry Quart sees in rademikibart the potential to address a longstanding unmet need in acute respiratory care.…
Korea Korea has something that very few countries can claim: high-quality healthcare data at genuine population scale JK Lee, Vice President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), outlines Korea’s transition from a generics-driven industry to a global innovation hub. He highlights the government’s strategic support, a growing pipeline…
Korea D&D Pharmatech is emerging as one of Korea’s most closely watched clinical-stage biotechnology companies, built on more than two decades of research into GLP-1 biology and peptide engineering. With programmes spanning MASH, neurodegenerative diseases, fibrosis, and oral peptide therapies, the company is translating scientific innovation into clinical progress while expanding…
Taiwan Biotechnology has long been a strategic priority for Taiwan’s economic development, standing alongside ICT and semiconductors as a key pillar of growth for the island. Driven by a highly educated scientific workforce and competitive development costs, Taiwan is a natural hub for early-phase drug development and initial manufacturing. However, only…
Taiwan Despite its modest market size, Taiwan is proving a popular investment destination for pharma and medtech multinationals. While the island’s semiconductor industry garners more headlines and revenues, life sciences is also growing as an investment sector. Taiwan is frequently near the front of the queue within APAC for new product…
USA Cell and gene therapies (CGTs) can now cure diseases that were untreatable a decade ago, often with a single dose. Yet most eligible patients – even those in rich countries like the United States – will never receive them. In many cases, the science is already in place. However, high…
Europe Few European pharmaceutical companies have undergone a transformation as striking as STADA’s. From its roots as a German generics business, the group has evolved into a diversified healthcare player with growing strength across Generics, Consumer Healthcare, and Specialty Pharmaceuticals, underpinned by an entrepreneurial culture and an increasingly important presence across…
Europe Nearly six years after becoming a standalone business, Merz Therapeutics is expanding beyond its neurotoxin heritage to build a broader specialty neurology platform across Europe and internationally. Newly appointed Region Europe Head Dan Staner discusses the company’s long-term ambitions in specialty neurology, while also reflecting on the growing importance of…
See our Cookie Privacy Policy Here
